Ernexa Therapeutics Inc.
ERNA
$1.47
-$0.0201-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -94.12% | 854.90% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -94.12% | 854.90% | -- |
| Cost of Revenue | -- | -- | -100.00% | -150.00% | -- |
| Gross Profit | -- | -- | 102.04% | 892.75% | -- |
| SG&A Expenses | -64.96% | -67.07% | -61.87% | -16.50% | 50.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.76% | -53.21% | -53.34% | -22.21% | 21.74% |
| Operating Income | 49.28% | 52.83% | 53.22% | 30.34% | -20.59% |
| Income Before Tax | 43.25% | -23.35% | 6.64% | -374.94% | -22.69% |
| Income Tax Expenses | 0.00% | 100.00% | 375.00% | 250.00% | -25.00% |
| Earnings from Continuing Operations | 43.23% | -23.39% | 6.40% | -375.84% | -22.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.23% | -23.39% | 6.40% | -375.84% | -22.65% |
| EBIT | 49.28% | 52.83% | 53.22% | 30.34% | -20.59% |
| EBITDA | 49.17% | 52.82% | 53.37% | 30.76% | -20.13% |
| EPS Basic | 96.04% | 87.49% | 86.79% | -375.84% | -20.07% |
| Normalized Basic EPS | 96.09% | 87.49% | 84.49% | -2.30% | -31.83% |
| EPS Diluted | 96.04% | 87.49% | 86.79% | -375.84% | -20.07% |
| Normalized Diluted EPS | 96.09% | 87.49% | 84.49% | -2.30% | -31.83% |
| Average Basic Shares Outstanding | 1,334.63% | 886.25% | 608.56% | 0.00% | 2.12% |
| Average Diluted Shares Outstanding | 1,334.63% | 886.25% | 608.56% | 0.00% | 2.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | 0.18% |